Key result
Cardiac CYP2U1 overexpression protects against diet-induced myocardial dysfunction and hypertrophy.
Why the study?
The role of cytochrome P450 2U1 (CYP2U1) in obesity-induced cardiomyopathy and its potential metabolic effects were unknown.
Does cardiac-specific overexpression of CYP2U1 alleviate myocardial dysfunction in a high-fat diet-induced mouse model of obesity cardiomyopathy?
Does cardiac-specific overexpression of CYP2U1 alleviate myocardial dysfunction in a high-fat diet-induced mouse model of obesity cardiomyopathy?
CYP2U1 overexpression protects against obesity-induced cardiomyopathy in mice by switching lipid metabolism away from pro-inflammatory pathways toward pro-resolving mediators.
Hypothesis-generating in mice; leaves open CYP2U1 modulation as a therapeutic target in human obesity cardiomyopathy.
Cytochrome P450 2U1 (CYP2U1) modulates lipid metabolism, yet its role in obesity-induced cardiomyopathy remains unknown. Here, we demonstrate that cardiac-specific overexpression of CYP2U1 safeguards against high-fat diet (HFD)-induced myocardial dysfunction. Mice received tail-vein injection of adeno-associated virus serotype 9 (AAV9) carrying CYP2U1 under the cardiac troponin T promoter (AAV9-cTnT-CYP2U1) and were maintained on a 16-week HFD. Cardiac-specific CYP2U1 overexpression was associated with better preservation of systolic function and with reduced myocardial hypertrophy, interstitial fibrosis, and cardiac inflammation. By combining transcriptomics, untargeted metabolomics, and oxylipidomics, we identified two protective mechanisms. Transcriptomic analysis indicated that CYP2U1 attenuated multiple inflammatory cascades, including nuclear factor-κB (NF-κB) p65 phosphorylation and nuclear translocation, with a corresponding reduction in interleukin-6 (IL-6) transcription; CCAAT/enhancer-binding protein β (C/EBPβ) may contribute to this regulation. Metabolomic analysis suggested that CYP2U1 remodels polyunsaturated fatty acid metabolism, consistent with a “metabolic switch” that shifts the balance away from pro-inflammatory arachidonic acid-derived hydroxyeicosatetraenoic acids (HETEs) toward the docosahexaenoic acid (DHA) pathway, with increased levels of the protective lipid mediators 19,20-epoxydocosapentaenoic acid (19,20-EDP) and protectin DX (PDX). In vitro, CYP2U1 overexpression in palmitic acid-challenged H9C2 cells reproduced these anti-inflammatory and metabolic features. CYP2U1 therefore limits obesity-driven cardiac inflammation by coupling suppression of the NF-κB/C/EBPβ–IL-6 axis with a shift in lipid mediators toward DHA-derived specialized pro-resolving mediators. Whether targeted activation of CYP2U1 can be translated into a therapeutic strategy for obesity-associated cardiomyopathy warrants further investigation.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2026) studied Obesity-induced cardiomyopathy. Cardiac-specific overexpression of CYP2U1 (AAV9-cTnT-CYP2U1) was evaluated on Myocardial dysfunction, hypertrophy, fibrosis, and inflammation. Cardiac-specific overexpression of CYP2U1 safeguarded mice against high-fat diet-induced myocardial dysfunction, hypertrophy, and cardiac inflammation by remodeling lipid metabolism.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: